...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
Q1 2016 Zenith Epigenetics Corporate Update
Zenith Q1 2016 Corporate Update presentation from the Biotech Showcase conference in San Francisco on January 12, 2016.
Posted by:
BearDownAZ
on
Jan 15, 2016 08:26PM
Zenith Epigenetics Conference Call Transcript May 13, 2015
Posted by:
BearDownAZ
on
Dec 07, 2015 11:18AM
Zenith Epigenetics Rodman & Renshaw Transcript Sept 8, 2013
Posted by:
BearDownAZ
on
Dec 07, 2015 11:16AM
1/7/16 Notice of Meeting and Management Information Circular
Posted by:
BearDownAZ
on
Dec 07, 2015 11:04AM
Zenith Special Meeting on June 30th (posted by Masila)
Posted by:
BearDownAZ
on
Dec 06, 2015 09:26PM